Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EU Extends Pilot Of New Drug Safety Reporting System

Executive Summary

Testing of the enhanced EU drug safety reporting system, EudraVigilance, is to be extended beyond February in an effort to gain more information on how stakeholders are finding the new requirements.

You may also be interested in...



EU Makes ISO Format Mandatory For Side-Effect Reporting From June 2022

Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.

EU Safety Signal Detection Pilot Extended Again

The pilot phase of a European project on new safety signal notification requirements has been extended for a second time following inconclusive results. 

EMA Outlines Regulatory Expectations On Use Of Patient Registries

Building on its ongoing patient registry initiative, the European Medicines Agency has issued recommendations on the methodological and operational aspects of the use of patient disease registries and registry studies for regulatory purposes.

Related Content

Topics

UsernamePublicRestriction

Register

PS124571

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel